Overall survival in *EGFR* mutated non-small-cell lung cancer patients treated with afatinib after *EGFR* TKI and resistant mechanisms upon disease progression

A. J. van der Wekken\(^1\)*, J. L. Kuiper\(^2\), A. Saber\(^3\), M. M. Terpstra\(^4\), J. Wei\(^4\), T. J. N. Hiltermann\(^1\), E. Thunnissen\(^5\), D. A. M. Heideman\(^5\), W. Timens\(^3\), E. Schuuring\(^3\), K. Kok\(^4\), E. F. Smit\(^2,6\), A. van den Berg\(^3\), H. J. M. Groen\(^1\)

\(^1\) Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, \(^2\) Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, Netherlands, \(^3\) Department of Pathology and Medical Biology, Groningen, University of Groningen, Groningen, Netherlands, \(^4\) University of Groningen, Department of Genetics, Groningen, Netherlands, \(^5\) Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands, \(^6\) Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands

* a.j.van.der.wekken@umcg.nl

Abstract

**Purpose**

To determine survival in afatinib-treated patients after treatment with first-generation *EGFR* tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors.

**Methods**

Characteristics and survival of patients treated with afatinib after resistance to erlotinib or gefitinib in two large Dutch centers were collected. Whole exome sequencing (WES) and pathway analysis was performed on available pre- and post-afatinib tumor biopsies and normal tissue.

**Results**

A total of 38 patients were treated with afatinib. T790M mutations were identified in 22/29 (76%) pre-afatinib treatment tumor samples. No difference in median progression-free-survival (2.8 months (95% CI 2.3–3.3) and 2.7 months (95% CI 0.9–4.6), \(p = 0.55\)) and median overall-survival (8.8 months (95% CI 4.2–13.4) and 3.6 months (95% CI 2.3–5.0), \(p = 0.14\)) were observed in T790M+ patients compared to T790M- mutations.

Somatic mutations in *TP53*, *ADAMTS2*, *CNN2* and multiple genes in the Wnt and PI3K-AKT pathway were observed in post-afatinib tumors of six afatinib-responding and in one non-responding patient. No new *EGFR* mutations were found in the post-afatinib samples of the six responding patients. Further analyses of post-afatinib progressive tumors revealed 28 resistant specific mutations in six genes (*HLA-DRB1*, *AQP7*, *FAM198A*, *SEC31A*, *PLOD1*, and *TTC20*).
*CNTLN*, and *ESX1*) in three afatinib responding patients. No known EGFR-TKI resistant-associated copy number gains were acquired in the post-afatinib samples.

**Conclusion**

No differences in survival were observed in patients with *EGFR*-T790M treated with afatinib compared to those without T790M. Tumors from patients who had progressive disease during afatinib treatment were enriched for mutations in genes involved in Wnt and PI3K-AKT pathways.

**Introduction**

Most patients with advanced non-small cell lung carcinoma (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations will develop resistance after 6–9 months of treatment with first generation reversible tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib[1,2]. The most common resistance mechanism is caused by the T790M gatekeeper mutation, and is detected in about half of the patients. Additional resistance-associated mechanisms are *MET* amplification, *HER2* mutations, transformation to small-cell lung cancer, expression of *IGFR1*, or alternative pathways to maintain PI3K/Akt signalling[3–7].

Because afatinib showed effectiveness in erlotinib resistant lung cancer models, afatinib effectiveness was studied in the Lux-Lung 4 study[8]. In this study patients with acquired resistance to first generation EGFR-TKIs exhibited a low response rate to afatinib and consequently the study did not meet its primary endpoint[9]. Reported resistance mechanisms to afatinib after first generation TKI are other mutations in *EGFR* (e.g. V843I), *FGFR1* amplification, upregulation of IL6R/JAK1/STAT3, glycolysis and Src pathways, and autophagy[10–17].

Pooled analysis of the Lux-Lung 3 and 6 trials showed a superior overall survival (OS) for first-line afatinib of 31.7 months for exon 19del *EGFR* mutations versus 20.7 months for the chemotherapy group (HR 0.59 (95%CI 0.45–0.77); p = 0.001). In contrast, no significant effect on OS of afatinib was observed in the L858R group (22.1 months versus 26.9 months in the chemotherapy group (HR 1.25 (95%CI 0.92–1.71); p = 0.16)[18]. Direct comparison of first-line gefitinib vs. afatinib treated patients revealed a significantly improved progression free survival (PFS) for patients treated with afatinib in a phase 2b trial[19]. Treatment of *EGFR*<sup>L858R/T790M</sup> mutant cell lines with rociletinib and osimertinib, targeting T790M, revealed a strong inhibition on cell growth[20]. In lung cancer patients, tumour responses with these compounds were observed in 58% and 68% of patients with T790M mutation, respectively[21,22].

The T790M mutation plays a role as mechanism of resistance after first line treatment with afatinib as well[23]. However, in an Eastern Asian study, T790M played no role in treatment outcome or the prognosis of patients treated with second-line afatinib indicating a similar effect on both T790M positive and negative tumour clones[24]. The development of late occurring T790M clones in tumours may go along with other resistant mechanisms than early developing T790M clones.

In this study we analysed survival of mostly white patients treated with afatinib after becoming resistant to erlotinib or gefitinib. In addition, we investigated the development of afatinib resistant associated mutations using whole exome sequencing (WES) in a subset of patients.
Materials and methods

Patient selection

Patients with relapsed advanced NSCLC whose tumour had progressed following initial disease control for more than 12 weeks with gefitinib or erlotinib and subsequently treated with afatinib 40 mg daily, partly on a compassionate use program, were enrolled, in two Dutch University Medical Centres (Free University Medical Centre and University Medical Centre Groningen)[25]. Patient characteristics including number of treatment lines, duration of previous EGFR-TKI exposure, the duration of afatinib use and PFS and OS were recorded. Informed consent for tumour tissue from all patients was obtained before biobanking and retrieval from the Groningen Pathology biobank and VUMC Pathology biobank. All patient data were anonymised and de-identified prior to analysis. The authors were not informed about identification variables. The study was approved by the Medical Ethical Committee of the University Medical Centre Groningen and conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Due to the retrospective nature of this study on biobanking material, under Dutch Law for human medical research (WMO), no specific written permission was compulsory from the Institutional Review Board.

Tumour response measurement

Tumour responses were assessed by comparing CT of chest and abdomen before start of afatinib, and every 6 weeks during treatment using RECIST version 1.1 criteria[26]. This means that if there was more than 30% shrinkage of the tumour and metastases, this was called a partial response (PR). If more than 20% growth of the tumour was found, this was called progressive disease (PD). Otherwise we called this stable disease (SD).

Tumour biopsies and diagnostic molecular analysis

Tumour biopsies were tested for the presence of EGFR mutations before and after treatment with erlotinib or gefitinib. Re-biopsies were taken for WES prior to start of afatinib and upon subsequent tumour progression. Paired blood or normal tissue was used as control to filter for personal variants. Briefly, 3-micron paraffin embedded tumour tissue sections were stained with haematoxylin and eosin and assessed for tumour content. Subsequent tissue sections of 10 micron were used for DNA isolation. Diagnostic testing for mutations was performed using high resolution melting analysis (HRM) for EGFR exons 18, 19, 20 and 21 (CCDS5514.1), for KRAS exon 2 for codon 12, 13, 61 (CCDS8702.1) and for BRAF exon 15 (NM_004333)[27,28]. PCR products with an abnormal HRM curve were re-amplified and subjected to Sanger sequencing to identify the mutation. ALK and ROS1 translocations were determined by Abbott FISH tests (Abbott 06N38-020 and Abbott 08N29-020), respectively.

Whole exome sequencing

In cases of tumour content less than 50%, laser microdissection (LMD6000, Leica, Wetzlar, Germany) was used. DNA from FFPE samples for WES was isolated using ReliaPrep™ FFPE gDNA Miniprep System kit (Promega, Madison, USA) following the protocol of the manufacturer. A standard salt-chloroform protocol was used to isolate DNA from blood. Quality control and WES were performed by BGI (BGI Tech Solutions Co. Ltd, Hong Kong). Raw image files were processed by Illumina base-calling Software 1.7 for base-calling with default parameters (Illumina Inc., San Diego, USA). Reads were aligned to the human 1000 genomes reference based on the GRCh37 build using BWA 5.9rc[29]. Picard tools were used for format conversion and marking duplicate
reads. Genome Analysis Toolkit (GATK) was used for indel realignment and base score quality recalibration (BSQR) by Molgenis Compute 4[30,31]. After using custom scripts in the VCF tools library, variant calling was performed using the GATK unified genotype and variant annotation by using SNPEFF/SNPSIFT 3.5 with the ensembl release 74 gene annotations http://www.ensembl.org/index.html, dbNSFP2.3, and GATK with annotations from the Database of Single Nucleotide Polymorphisms (dbSNP) Bethesda (MD): National Centre for Biotechnology Information, National Library of Medicine (dbSNP Build ID: 137) and CosmicCodingMuts_v62[32–35]. For mutations with a moderate impact according to SNPEFF, we used the CADD value to discriminate between mutations with a possible (CADD score >10) or a probable effect (CADD >20) on protein function. Exome sequencing data have been deposited on European Nucleotide Archive (ENA) website and are available under accession number: PRJEB21459 (http://www.ebi.ac.uk/ena/data/view/PRJEB21459).

Identification of afatinib resistance associated mutations

Different criteria were used to identify mutations associated with resistance to afatinib treatment. First, we eliminated variants with a total read count of less than 10 in corresponding normal DNA, as we were not able to exclude them as personal variants (step 1). Then, we excluded germline variants based on mutant read count of more than one and a total read count of 10–49, or mutant read count of more than two and a total read count of ≥50 in the normal DNA (steps 2 and 3). The remaining variants were regarded as true somatic mutations. Next, we filtered out variants with less than 10x coverage in either primary or resistant biopsies (step 4), as read counts for these variants are too low to be used for identification of afatinib resistance associated mutations.

As we did not have pre-afatinib tumour sample for all seven patients, that also had post-afatinib samples, we followed two different strategies to identify potential resistance-related mutations: a) for all seven patients with adequate tumour samples we generated a list of genes having a mutation in the resistant sample irrespective of having a pre-afatinib sample or not, b) for 3 out of 7 patients with both pre- and post-afatinib samples, we selected variants with a more than two times higher mutant read frequency (MRF) in the resistant versus the primary biopsy (MRF_R >2*MRF_P; step 5).

In the final step of both analyses, we only included variants with a mapping quality >20 and a quality score >20. Genes found in this analysis were browsed in the Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [accessed JUL-2016] to screen for any remaining known single nucleotide variants (SNVs). The COSMIC database was used to compare identified mutations in our cohort to the reported somatic mutations in cancer (http://cancer.sanger.ac.uk/cosmic) [accessed AUG-2016].

Pathway analysis

Partek Genomics Suite 6.6 (Partek Inc., St Louis, MO) was used to link mutated genes to either particular pathways only or whether they belonged to the same pathways.

WES-based copy number variant analysis (CNV)

Pseudo probe data were generated with VarScan2 and Samtools as described previously by Koboldt et al. and Li et al.[36,37]. Briefly, for each sample the pseudo probe derived GC-normalized log2 copy number ratios were generated by dividing the read counts of the tumour sample by the read counts of the corresponding normal sample. All alignments with a mapping quality greater than 40 in combination with a minimal segment size of 2kb and a maximal segment size of 5kb with a mean coverage of at least one were used to calculate the log2 ratios.
CNV plots of the post-afatinib tumour were compared to the CNV plot of the pre-afatinib tumour of the same patient by a combination of calculated ratios and visual inspection.

Statistical analysis

Descriptive statistics were used for the patient characteristics. Objective tumour response rate (ORR) was defined as the best response to treatment of complete response (CR) or partial response (PR) according to RECIST 1.1[26]. PFS was defined as the time from start of first generation TKI or start of afatinib in calculating PFS of erlotinib and gefitinib or afatinib treatment, respectively, until progressive disease (PD) according to RECIST 1.1 or death and OS was defined as the time from start of these treatments until death or lost to follow up. Patients who had not progressed at data cut-off were censored at the last day of follow-up. PFS and OS were estimated with Kaplan-Meier survival curves using log-rank test for estimating group differences. Chi-square Test was used to compare group variables. P-values <0.05 were considered significant. Statistical analyses were performed with SPSS-Statistics version 22.0 (IBM corporation, Armonk, NY, USA).

Results

Study population

Between April 2009 and January 2014, 38 patients with advanced adenocarcinoma of the lung, from two Dutch university hospitals, were treated with afatinib (S1 Fig). Follow-up was more than 18 months after the last patient was included. All patients received gefitinib or erlotinib prior to afatinib, two patients received erlotinib, followed by gefitinib. A platinum doublet was given as first line treatment to 24 patients before treatment with first generation TKI and afatinib (Fig 1).

Efficacy of 1st line and 2nd line TKI treatments

Median PFS on first-line erlotinib or gefitinib TKI treatment in those who turned out to be T790M positive (n = 22) and negative (n = 7) in later biopsies showed a trend to be different, 13.3 months (95% CI., 10–17) and 8.1 months (95% CI., 0–16) respectively (p = 0.06; Fig 1).

Tumour response rate of all 38 patients on second line afatinib was 18% and the disease control rate was 79%. Median PFS on afatinib was 2.8 months (95% CI., 2.3–3.2) and median OS was 6.9 months (95% CI., 1.5–12.4).

Survival by mutation type in afatinib treated patients

Median PFS of afatinib treated patients with (n = 22) and without (n = 7) T790M mutation was similar with 2.8 months (95% CI 2.3–3.3) and 2.7 months (95% CI 0.9–4.6), respectively (p = 0.55; Fig 1). Median OS was numerical better in the T790M positive as compared to the T790M negative group, although not significant (8.8 months (95% CI, 4.2–13.4) and 3.6 months (95% CI, 2.3–5.0); p = 0.14; Fig 2).

EGFR mutational analysis

The first biopsy was taken before start of any TKI treatment (n = 38). Thirty-three patients had activating EGFR mutations, the most common mutation was a deletion in exon 19 (87%; n = 24) (Table 1); no T790M mutations were observed in any of the biopsies taken before EGFR-TKI. Four patients with wild type EGFR and one patient with no test result available were included based on Jackman’s criteria (TKI treatment with at least stable disease for 6 months)[25]. None of those five patients had KRAS or BRAF mutations or ALK and ROS1 translocations.
A second biopsy taken after failure on erlotinib or gefitinib was available of twenty-nine EGFR+ patients. In 22/29 (76%) patients with a known activating EGFR mutation the T790M mutation was detected as a second mutation. The presence of a T790M mutation was significantly more common in patients treated with erlotinib alone (18/19; 95%) compared to patients treated with gefitinib alone (2/8; 25%, p<0.001; Table 2). The two patients treated with erlotinib and gefitinib were excluded from this comparison. No cancer cell transformation has been observed in our population.

Whole exome sequencing (WES)

Out of the 18 patients with a post-afatinib biopsy, there was enough tumour tissue to perform WES in six patients. Normal, pre- and post-afatinib samples were available in 3 of the 6 responding patients (#2, 5 and 6) and only normal and post-afatinib samples with sufficient DNA quality were available from the other three patients (#1, 4 and 7). In only one (patient #3) out of nine non-responders to afatinib, there was enough tumour tissue in the pre-afatinib biopsy. Of the non-responding patient we analysed pre-afatinib normal and tumour tissue samples.

In the initial analyses we focused on recurrently mutated genes found in at least 2 of the 7 biopsies irrespective of presence of the mutation in the pre-treatment biopsy. This revealed presence of 284 mutations in 68 genes (S1 Table). According to putative damaging effect according to CADD a high score (>20) was found for 27 mutations in 25 genes, e.g. TP53,
DYNC2H1, MGA, USH2A, ROBO2, TEX15, ADAMTS2, CUL7, IL33, ADAMTS12, CNN2, CNKSR3, LAMA3, EML6, TTN, KNDC1, EPB41, PKHD1L1, KHL23, EVPL, CACNA2D1, CDC27, KCNT2, ASTN2 and MROH2B. A moderate CADD score (10–20) and/or recurrent mutations were found for 110 mutations in 45 genes, e.g., OR8U1, MUC16, MUC6,

Table 1. EGFR mutation status in tumor biopsies of a cohort of 38 advanced NSCLC patients.

<table>
<thead>
<tr>
<th>EGFR mutation</th>
<th>First biopsy (n = 38)</th>
<th>Pre-afatinib biopsy (n = 33)</th>
<th>Post-afatinib biopsy (N = 18)</th>
<th>WES (N = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon 18</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Exon 19</td>
<td>24</td>
<td>4</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Exon 19 + T790M</td>
<td>18</td>
<td>6</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Exon 21</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Exon 21 + T790M</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Exon 18 + 20</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>WT</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Exon 18 + 21 + T790M</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Mutation analysis not possible</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

A diagnostic biopsy taken before erlotinib and/or gefitinib treatment is called first biopsy; A biopsy after first generation EGFR-TKI is called pre-afatinib biopsy. Biopsy taken in patients who responded to afatinib and underwent a biopsy afterwards is called post-afatinib biopsy. WT: wild type.

https://doi.org/10.1371/journal.pone.0182885.t001

Table 2. Patient characteristics of the afatinib treated group according to T790M mutation.

<table>
<thead>
<tr>
<th></th>
<th>T790M + (N = 22)</th>
<th>T790M − (N = 7)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (years; range)</td>
<td>60 (32–81)</td>
<td>56 (44–67)</td>
<td>0.45</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>0.55</td>
</tr>
<tr>
<td>Male</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>18</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>ECOG Performance status</td>
<td></td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>0</td>
<td>12</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>9</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Ethnic origin</td>
<td></td>
<td></td>
<td>0.49</td>
</tr>
<tr>
<td>White</td>
<td>19</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Afro-American</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Smoking history (at start afatinib treatment)</td>
<td></td>
<td></td>
<td>0.33</td>
</tr>
<tr>
<td>Never smoker</td>
<td>10</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>10</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Number of lines of previous chemotherapy</td>
<td></td>
<td></td>
<td>0.29</td>
</tr>
<tr>
<td>0</td>
<td>11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>&gt;2</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>EGFR TKI before afatinib</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>erlotinib</td>
<td>18</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>gefitinib</td>
<td>2</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>both subsequently</td>
<td>4</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

https://doi.org/10.1371/journal.pone.0182885.t002
ANKRD36C, HLA-DRB5, DYNC2H1, NEFH, FASLG, MUC5B, PRSS3, HYDIN, MGA, USH2A, TAS2R43, GPR98, C4BPB, DOCK2, INVS, CUL7, NHSL2, USP24, TP53R, MUC12, OR2T4, CN2, CNKSR3, LAMA3, TTN, KNDC1, EPB41, EVPL, FZR1, CACNA2D1, CDC27, KCNT2, EMP2, MST1, ARHGA32, NLGN4X, HLAQA1, HERC2, ASTN2, SP8, PRSS1 and MROH2B. CNN2 is the only gene with an identical high CADD score mutation in 2 patients. Some of the other recurrently mutated genes had mixed high and moderate CADD scores. In total, 137 mutations in 48 genes were identified as potentially involved in afatinib resistance.

In patient #7 treated with afatinib according to Jackman’s criteria, without a known EGFR mutation, WES revealed activation mutations in EGFR, e.g. G719C and a L861Q. In the other six patients, no new EGFR mutations were identified. For the three pre-afatinib samples this was consistent with the targeted diagnostic mutation tests.

In patients #2, 5, and 6 (Table 3) WES data of normal tissue, pre- and post-afatinib tumour samples could be analysed.

Four hundred forty five mutations in 367 genes (range 87–216) had higher MRF, or were specific, for the post-afatinib treatment sample. Mutations in these genes might have contributed to the observed afatinib resistance. Six genes, with in total 28 mutations, were recurrently mutated in at least two out of three patients, i.e. HLA-DRB1, AQP7, FAM198A, SEC31A, CNTLN, and ESX1.

Most of the mutations observed in HLA-DRB1 were also present in the ExAc database and therefore appear to be less important. The other mutations, absent in the ExAc database but present in the COSMIC database (in different tumour types), might be relevant, such as p. W38Fs in HLA-DRB1, p.Q30fs in AQP7, p.C135R in TP53, p.Q220 in HLA-DRB5, p.G8V in PRSS3, p. S1155R in USH2A and p.V521I in KCNT2. The p.K41T mutation in HLA-DRB1, p. IT255T and p. Q136E in TP53 and p. P2811S in USH2A are also described in human lung cancer samples. The p.P95S mutation in AQP7 was observed in patients #1 and #5.

Pathway analysis of all genes mutated in any of the 7 analysed patients indicated that most of the mutated genes were members of Wnt signalling (S2 Fig) and PI3K-AKT (S3 Fig) pathways. In addition, we observed mutations in two genes of the glycolysis pathway (Table 4). We did not identify mutations in genes related to the pathways known to be associated with afatinib resistance, e.g. autophagy and IL6R/JAK/STAT.

**Copy number variations**

We observed only a few changes in copy number variations (CNV) between the pre- and post-afatinib samples. In patient #2 copy number gain (CNG) of part of chromosome 5, 8, 11 and 16 and loss of part of chromosome 4 and 14 was observed (S4A Fig). In patient #5 no differences in CNV between pre- and post-afatinib biopsies was observed (S4B Fig). In patient #6, copy number loss was seen only for part of chromosome X (S4C Fig). Specifically, no CNV aberrations in MET, FGFR1, Src or genes involved in the IL6/JAK1/STAT3 pathway were found.

**Discussion**

In this study we investigated afatinib resistance in patients with relapsed advanced NSCLC whose tumour had progressed on gefitinib or erlotinib and subsequently were treated with afatinib. In 38 patients with an EGFR mutation or treated with TKIs according to Jackman’s criteria we first determined the relevance of erlotinib and gefitinib in inducting T790M mutation in EGFR. The exon 20 T790M mutation was detected under EGFR-TKI selection pressure in re-biopsies of 22/29 (76%) patients in our cohort. This percentage is slightly above the upper range that has been reported in the literature (25–63%)[38–40]. The percentage of T790M + patients was significantly higher in the erlotinib treated as compared to the gefitinib treated
patients. In the literature there is a trend that T790M mutations are numerically higher in patients who received erlotinib[41]. The duration of first line reversible TKIs did not influence the occurrence of a T790M mutation. In our cohort of afatinib treated patients, PFS (2.8 months) and OS (9.2 months) were similar to the Lux-Lung 1 study[42]. We did not find an influence of the pre-afatinib treatment induced T790M mutation on response outcome (PFS or OS) on second line afatinib treatment. This is consistent with the study of Sun et al. on an Asian population. In contrast Landi et al. found no tumour response with afatinib in T790M positive patients. In the current literature discrepancy is observed in the tumour response to afatinib in T790M positive patients[24,43].

To understand molecular events underlying progression of disease on afatinib treatment, WES was performed in all patients with sufficient tumour tissue to identify known and novel resistance mechanisms. We observed 68 recurrently mutated genes in 7 different patients with

### Table 3. Recurrently mutated genes in tumors from patients who progressed under afatinib.

<table>
<thead>
<tr>
<th>GENE</th>
<th>PATIENT</th>
<th>CHROM</th>
<th>POS</th>
<th>REF</th>
<th>ALT</th>
<th>AA CHANGE</th>
<th>CADD score</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-DRB1</td>
<td>#2</td>
<td>6</td>
<td>32552130</td>
<td>C</td>
<td>A</td>
<td>R42S</td>
<td>0.145</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>32552131</td>
<td>C</td>
<td>G</td>
<td>R42T</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>#3</td>
<td></td>
<td>32552134</td>
<td>T</td>
<td>G</td>
<td>K41T</td>
<td>10.93</td>
</tr>
<tr>
<td></td>
<td>#7</td>
<td></td>
<td>32552130</td>
<td>C</td>
<td>A</td>
<td>R42S</td>
<td>0.145</td>
</tr>
<tr>
<td></td>
<td>#4</td>
<td></td>
<td>32552132</td>
<td>T</td>
<td>A</td>
<td>R42W</td>
<td>10.52</td>
</tr>
<tr>
<td></td>
<td>#2</td>
<td>9</td>
<td>32548544</td>
<td>T</td>
<td>G</td>
<td>I248L</td>
<td>16.04</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>32552130</td>
<td>C</td>
<td>A</td>
<td>R42S</td>
<td>0.145</td>
</tr>
<tr>
<td></td>
<td>#5</td>
<td></td>
<td>32552131</td>
<td>C</td>
<td>G</td>
<td>R42T</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>#4</td>
<td></td>
<td>32552137</td>
<td>G</td>
<td>C</td>
<td>P40R</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>#2</td>
<td>3</td>
<td>32552138</td>
<td>G</td>
<td>C</td>
<td>P40A</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>#7</td>
<td></td>
<td>32552143</td>
<td>C</td>
<td>T</td>
<td>W38*</td>
<td>13.84</td>
</tr>
<tr>
<td></td>
<td>#4</td>
<td></td>
<td>32552144</td>
<td>A</td>
<td>C</td>
<td>W38G</td>
<td>3.518</td>
</tr>
<tr>
<td>AQP7</td>
<td>#2</td>
<td>9</td>
<td>33385808</td>
<td>G</td>
<td>T</td>
<td>N194K</td>
<td>15.08</td>
</tr>
<tr>
<td></td>
<td>#5</td>
<td></td>
<td>33385709</td>
<td>C</td>
<td>T</td>
<td>V96L</td>
<td>9.787</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>33385712</td>
<td>G</td>
<td>A</td>
<td>P95S</td>
<td>10.22</td>
</tr>
<tr>
<td></td>
<td>#5</td>
<td></td>
<td>33385690</td>
<td>C</td>
<td>T</td>
<td>R234S</td>
<td>14.5</td>
</tr>
<tr>
<td></td>
<td>#1</td>
<td></td>
<td>33385698</td>
<td>A</td>
<td>G</td>
<td>L231P</td>
<td>16.61</td>
</tr>
<tr>
<td></td>
<td>#4</td>
<td></td>
<td>33385712</td>
<td>G</td>
<td>A</td>
<td>P95S</td>
<td>10.22</td>
</tr>
<tr>
<td></td>
<td>#2</td>
<td>3</td>
<td>43074734</td>
<td>C</td>
<td>A</td>
<td>P327T</td>
<td>9.704</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>43074337</td>
<td>G</td>
<td>T</td>
<td>W194C</td>
<td>14.09</td>
</tr>
<tr>
<td>SEC31A</td>
<td>#5</td>
<td>4</td>
<td>83803067</td>
<td>C</td>
<td>T</td>
<td>R8H</td>
<td>27.8</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>83784534</td>
<td>G</td>
<td>T</td>
<td>W194C</td>
<td>14.09</td>
</tr>
<tr>
<td>CNTLN</td>
<td>#2</td>
<td>9</td>
<td>17366624</td>
<td>TGAA</td>
<td>T</td>
<td>E633</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>#5</td>
<td></td>
<td>17236574</td>
<td>TG</td>
<td>T</td>
<td>A280</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>17236576</td>
<td>C</td>
<td>A</td>
<td>A280E</td>
<td>5.077</td>
</tr>
<tr>
<td>ESX1</td>
<td>#2</td>
<td>X</td>
<td>103497493</td>
<td>G</td>
<td>C</td>
<td>R175G</td>
<td>11.68</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td></td>
<td>103498982</td>
<td>C</td>
<td>A</td>
<td>G120V</td>
<td>14.79</td>
</tr>
</tbody>
</table>

Tumor samples were from 3 patients (#2, #5 and #6) with WES data of normal, primary and resistant tumors and from patients with samples from resistant tumors only.

chrom, chromosome; pos, basepair location; ref/alt, reference and altered nucleotides at mutated position; AA change, amino acid change; CADD, Combined Annotation Dependent Depletion score; CADD score ≥10 indicates a position within the top 10% most deleterious mutations. A score of ≥20 indicates a position within the top 1% most deleterious mutations.

https://doi.org/10.1371/journal.pone.0182885.t003
Glycolysis ADPGK LDH6A
Autophagy
IL6/JAK/STAT
Wnt MAPK8 TP53 TP53 FOSL1 PLCB4 WNT9B INVS AXIN1 TP53
LEF1 TP53 FZD10
APE2
PI3K-AKT COL4A4 ITGA2 PPP2R2B EGFR LAMC3 EGF EGF EGF EGFR TP53 KDR
EGFR PIK3CA EGFR LAMB3 FASLG RELN
VWF PIK3CG COL1A2 PTEN FASLG
TSC2 COL4A5 FASLG TP53
TP53
A: resistant biopsy specific based on MRF R > 2x MRF P, B: mutation present in both pre and post afatinib biopsy based on MRF R < 2x MRF P and MRF R > 0, C: mutation in resistant biopsy based on MRF R > 0, D: mutation in pre-afatinib biopsy in non-responding patient based on MRF P > 0; italic: present in other primary samples. N: normal tissue or buffy coat, P: biopsy before afatinib treatment, R: biopsy after afatinib treatment.
In conclusion, no differences in survival were observed in patients with \textit{EGFR} T790M treated with afatinib compared to those without T790M. Potential mechanism of resistance to afatinib treatment might be related to mutations in \textit{HLA-DRB1}, \textit{AQP7}, \textit{TP53}, \textit{HLA-DRB5}, \textit{PRSS3}, \textit{USH2A}, \textit{KCNT2} and \textit{CNN2} and to mutations in genes of the Wnt and PI3K-AKT pathways.

**Supporting information**

S1 Table. Recurrently mutated genes in tumor samples from patients resistant to afatinib without information from primary biopsies using whole exome sequencing chrom, chromosome; pos, bp location; ref/alt, reference and altered nucleotides at mutated position; AA change, amino acid change; CADD, Combined Annotation Dependent Depletion score; CADD score $\geq 10$ indicates a position within the top 10\% most deleterious mutations. A score of $\geq 20$ indicates a position within the top 1\% most deleterious mutations.

(S1 Table)

S1 Fig. Overview of treatment in 38 patients administered per treatment line. Organogram of 38 treated patients where afatinib is given in different treatment lines (1–5). Chemotherapy was variable, e.g. cisplatinum/pemetrexed, carboplatinum/paclitaxel/bevacizumab, docetaxel, pemetrexed.

(TIF)

S2 Fig. Wnt signaling pathway involved in afatinib resistant tumours. Color boxes are the different mutations found in different samples. Multiple mutated genes involved in the Wnt pathway are shown.

(TIF)

S3 Fig. PIK3-AKT signaling pathway involved in afatinib resistant tumours. Color boxes are the different mutations found in different samples.

(TIF)

S4 Fig. Overview of copy numbers and their aberrations in patients #2, #5 and #6. Overview of the copy numbers and allele frequencies of pre-afatinib (top) and post-afatinib biopsies (bottom) in patients 2 (A), 5 (B) and 6 (C). The boxes indicate aberrations between pre-afatinib and post-afatinib biopsies with either copy number gain or loss.

(TIF)

**Acknowledgments**

Tineke van der Sluis for technical assistance.

**Author Contributions**

**Conceptualization:** A. J. van der Wekken, A. Saber, W. Timens, K. Kok, E. F. Smit, A. van den Berg, H. J. M. Groen.

**Data curation:** A. J. van der Wekken, J. L. Kuiper, A. Saber, M. M. Terpstra, E. Schuuring, K. Kok, E. F. Smit, A. van den Berg, H. J. M. Groen.

**Formal analysis:** A. J. van der Wekken, A. Saber, M. M. Terpstra, J. Wei, K. Kok, A. van den Berg, H. J. M. Groen.

**Investigation:** A. J. van der Wekken, J. L. Kuiper, M. M. Terpstra, A. van den Berg, H. J. M. Groen.


Software: M. M. Terpstra, K. Kok.


Validation: D. A. M. Heideman, E. Schuuring, A. van den Berg.


Writing – original draft: A. J. van der Wekken, J. L. Kuiper, A. Saber, M. M. Terpstra, J. Wei.


References


